---
layout: default
title: Ocrelizumab
parent: 僅模型預測 (L5)
nav_order: 57
evidence_level: L5
indication_count: 5
---

# Ocrelizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the evidence pack as provided (no code changes involved, so I'm proceeding directly to report generation per the template). A few data-integrity notes before the report:

- `drug.original_indications` is empty and `original_moa` is flagged `[Data Gap]` — I have **not** substituted outside knowledge for these; the report states plainly that this data is missing rather than guessing.
- `taiwan_regulatory.licenses` is empty (0 authorizations) — per the "omit empty sections" rule, the Norway Market Information table is omitted rather than shown empty.
- Ocrelizumab is not classified as antineoplastic anywhere in this evidence pack (no DrugBank category, no original-indication keyword, not a cytotoxic chemo class) — the Cytotoxicity section is therefore omitted.
- For rank 4 ("breast tumor luminal A or B"), the pack's own `repurposing_rationale` explicitly flags the 19 "literature" hits as false-positive keyword matches (B-cell/HLA-B/hepatitis-B papers) rather than real evidence — I carried that caveat into the conclusion instead of treating the raw count of 19 as supporting evidence.

---

# Ocrelizumab: From Unspecified Original Indication to HER2 Positive Breast Carcinoma

## One-Sentence Summary

Ocrelizumab (DrugBank ID DB11988) is an anti-CD20 B-cell depleting monoclonal antibody; its original approved indication is not captured in this evidence pack (flagged as a data gap). The TxGNN model predicts it may be effective for **HER2 Positive Breast Carcinoma**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, representing a model-prediction-only hypothesis with no established biological rationale.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in this evidence pack (data gap — see Conclusion) |
| Predicted New Indication | HER2 Positive Breast Carcinoma |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap DG002, High severity). Based on information present elsewhere in this evidence pack, ocrelizumab is qualitatively known as an anti-CD20 B-cell depleting monoclonal antibody.

The predicted indication, HER2 positive breast carcinoma, is driven by ERBB2 (HER2) receptor tyrosine kinase overexpression — a signaling pathway with no established biological or pharmacological overlap with CD20-mediated B-cell depletion. The evidence pack's own repurposing rationale states this explicitly: the connection reflects proximity in the TxGNN embedding space, not a validated mechanistic or clinical relationship.

Because there is no supporting clinical trial or published literature for this pairing, and no plausible mechanistic bridge between the drug's known pharmacology and the predicted tumor biology, this candidate should be treated as a purely computational hypothesis rather than a clinically actionable lead at this stage.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- Zero clinical trials and zero peer-reviewed literature support ocrelizumab for HER2 positive breast carcinoma. All five TxGNN-ranked breast cancer subtypes evaluated for this drug (HER2+, normal breast-like, PR+, luminal A/B, PR−) share this same L5 evidence level, and none has an established mechanistic rationale.
- A Blocking-severity data gap (DG001: missing TFDA/label warnings and contraindications) means this candidate cannot complete even the S1 safety pre-screen, independent of the efficacy evidence gap.

**To proceed, the following is needed:**
- TFDA/regulatory package insert (warnings, contraindications) to close the Blocking data gap (DG001)
- Confirmed mechanism-of-action data (DG002) to establish or rule out a biological rationale linking anti-CD20 B-cell depletion to HER2-driven or hormone-receptor-driven breast cancer pathways
- Prospective preclinical or translational studies testing ocrelizumab specifically in HER2+ breast cancer models, since none currently exist
- Manual re-verification of any future "breast tumor luminal A or B" literature hits — the 19 PubMed results retrieved for that candidate were reviewed and found to be false-positive keyword matches (B-cell developmental biology, hepatitis-B vaccine, and HLA-B typing papers), not genuine breast cancer evidence
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

